Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
It is intended as an evidence-based reference for patients, dietitians, pharmacists and prescribers seeking clarity on how to maintain micronutrient adequacy during GLP-1 therapy
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma
More details are available on the IV therapy insurance coverage page
Highlights include: The race to develop long-acting, oral, and inhalable formulations Insights into AI-driven peptide design and transdermal delivery potential Analytical hurdles in characterizing complex synthetic peptides Perspectives from Novo Nordisk, Waters, Charles River, DFE Pharma, and more A look at novel indicationsfrom cardiovascular protection to alcohol use disorder and cognitive decline Whether youre driving GLP-1 innovation, optimizing delivery platforms, or evaluating market opportunities, this eBook delivers timely intelligence to inform your strategy
R.BrownF
US$ 24.95
US$ 22.21
/assets/images/provider/photos/2775905.jpeg)
US$ 22.12
US$ 26.10
